RS Oncology

News & Events

Press Release July 14, 2026

RS Oncology's PRX3 Inhibitor (RSO-021) Shows Promise in Fight Against Deadly Mesothelioma, Rooted in Discovery Science from the University of Vermont

Read Article ↗
Publication July 14, 2026

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer

Read Article ↗